Cargando…

EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus

OBJECTIVES: The objectives of this study were to investigate the discriminative ability of EQ-5D-3L full health state (FHS) in clinical trials of SLE, and to identify factors associated with FHS after treatment. METHODS: Data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials of belim...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindblom, Julius, Gomez, Alvaro, Borg, Alexander, Emamikia, Sharzad, Ladakis, Dimitris , Matilla, Joaquin, Pehr, Martin, Cobar, Flordelyn, Enman, Yvonne, Heintz, Emelie , Regardt, Malin, Parodis, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487305/
https://www.ncbi.nlm.nih.gov/pubmed/33502473
http://dx.doi.org/10.1093/rheumatology/keab080
_version_ 1784577928084848640
author Lindblom, Julius
Gomez, Alvaro
Borg, Alexander
Emamikia, Sharzad
Ladakis, Dimitris 
Matilla, Joaquin
Pehr, Martin
Cobar, Flordelyn
Enman, Yvonne
Heintz, Emelie 
Regardt, Malin
Parodis, Ioannis
author_facet Lindblom, Julius
Gomez, Alvaro
Borg, Alexander
Emamikia, Sharzad
Ladakis, Dimitris 
Matilla, Joaquin
Pehr, Martin
Cobar, Flordelyn
Enman, Yvonne
Heintz, Emelie 
Regardt, Malin
Parodis, Ioannis
author_sort Lindblom, Julius
collection PubMed
description OBJECTIVES: The objectives of this study were to investigate the discriminative ability of EQ-5D-3L full health state (FHS) in clinical trials of SLE, and to identify factors associated with FHS after treatment. METHODS: Data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials of belimumab (N = 1684) were utilized. FHS was defined as a response of no problems in all five EQ-5D-3L dimensions, yielding an index score of 1. The Pearson’s χ(2) or Fisher’s exact test was employed for comparisons, and logistic regression for adjustments and assessment of independence. RESULTS: We demonstrated higher EQ-5D-3L FHS frequencies among patients given standard therapy (ST) plus the licensed belimumab dose vs ST alone (26.1% vs 19.4%; P = 0.001; week 52), and within SRI-4 responders vs non-responders (27.0% vs 19.8%; P < 0.001; week 52) from weeks 36 to 52. In multivariable regression analysis, SLEDAI-2K (OR: 0.90; 95% CI: 0.87, 0.94; P < 0.001) and SLICC/ACR Damage Index (OR: 0.79; 95% CI: 0.69, 0.91; P = 0.001) scores were independently associated with lower FHS frequencies at week 52, while adding monthly infusions of belimumab 10 mg/kg to ST favoured FHS perception (OR: 1.60; 95% CI: 1.15, 2.24; P = 0.006). Add-on belimumab 10 mg/kg yielded higher FHS frequencies in antimalarial users vs non-users (29.9% vs 20.1%; P = 0.011), and in anti-dsDNA- and anti-Sm- positive vs negative patients (31.4% vs 13.4%; P < 0.001 and 33.0% vs 22.6%; P = 0.010, respectively), whereas no significant differences were observed in patients given ST alone. CONCLUSION: EQ-5D-3L FHS distinguished belimumab from placebo and responders from non-responders, and exhibited known-group validity in subgroup analysis. FHS may prove a useful patient-reported outcome in SLE studies.
format Online
Article
Text
id pubmed-8487305
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-84873052021-10-04 EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus Lindblom, Julius Gomez, Alvaro Borg, Alexander Emamikia, Sharzad Ladakis, Dimitris  Matilla, Joaquin Pehr, Martin Cobar, Flordelyn Enman, Yvonne Heintz, Emelie  Regardt, Malin Parodis, Ioannis Rheumatology (Oxford) Clinical Science OBJECTIVES: The objectives of this study were to investigate the discriminative ability of EQ-5D-3L full health state (FHS) in clinical trials of SLE, and to identify factors associated with FHS after treatment. METHODS: Data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials of belimumab (N = 1684) were utilized. FHS was defined as a response of no problems in all five EQ-5D-3L dimensions, yielding an index score of 1. The Pearson’s χ(2) or Fisher’s exact test was employed for comparisons, and logistic regression for adjustments and assessment of independence. RESULTS: We demonstrated higher EQ-5D-3L FHS frequencies among patients given standard therapy (ST) plus the licensed belimumab dose vs ST alone (26.1% vs 19.4%; P = 0.001; week 52), and within SRI-4 responders vs non-responders (27.0% vs 19.8%; P < 0.001; week 52) from weeks 36 to 52. In multivariable regression analysis, SLEDAI-2K (OR: 0.90; 95% CI: 0.87, 0.94; P < 0.001) and SLICC/ACR Damage Index (OR: 0.79; 95% CI: 0.69, 0.91; P = 0.001) scores were independently associated with lower FHS frequencies at week 52, while adding monthly infusions of belimumab 10 mg/kg to ST favoured FHS perception (OR: 1.60; 95% CI: 1.15, 2.24; P = 0.006). Add-on belimumab 10 mg/kg yielded higher FHS frequencies in antimalarial users vs non-users (29.9% vs 20.1%; P = 0.011), and in anti-dsDNA- and anti-Sm- positive vs negative patients (31.4% vs 13.4%; P < 0.001 and 33.0% vs 22.6%; P = 0.010, respectively), whereas no significant differences were observed in patients given ST alone. CONCLUSION: EQ-5D-3L FHS distinguished belimumab from placebo and responders from non-responders, and exhibited known-group validity in subgroup analysis. FHS may prove a useful patient-reported outcome in SLE studies. Oxford University Press 2021-01-27 /pmc/articles/PMC8487305/ /pubmed/33502473 http://dx.doi.org/10.1093/rheumatology/keab080 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
Lindblom, Julius
Gomez, Alvaro
Borg, Alexander
Emamikia, Sharzad
Ladakis, Dimitris 
Matilla, Joaquin
Pehr, Martin
Cobar, Flordelyn
Enman, Yvonne
Heintz, Emelie 
Regardt, Malin
Parodis, Ioannis
EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
title EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
title_full EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
title_fullStr EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
title_full_unstemmed EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
title_short EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
title_sort eq-5d-3l full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487305/
https://www.ncbi.nlm.nih.gov/pubmed/33502473
http://dx.doi.org/10.1093/rheumatology/keab080
work_keys_str_mv AT lindblomjulius eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus
AT gomezalvaro eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus
AT borgalexander eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus
AT emamikiasharzad eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus
AT ladakisdimitris eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus
AT matillajoaquin eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus
AT pehrmartin eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus
AT cobarflordelyn eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus
AT enmanyvonne eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus
AT heintzemelie eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus
AT regardtmalin eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus
AT parodisioannis eq5d3lfullhealthstatediscriminatesbetweendrugandplaceboinclinicaltrialsofsystemiclupuserythematosus